Sigilon Therapeutics Competitors

Nuvation Bio (NYSE:NUVB) and Sigilon Therapeutics (NASDAQ:SGTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Nuvation Bio and Sigilon Therapeutics, as reported by MarketBeat.

Nuvation Bio currently has a consensus target price of $17.40, suggesting a potential upside of 74.00%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Nuvation Bio.

Valuation and Earnings

This table compares Nuvation Bio and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Nuvation Bio and Sigilon Therapeutics' net margins, return on equity and return on assets.

Summary

Nuvation Bio beats Sigilon Therapeutics on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for ImmunityBio and Sigilon Therapeutics, as reported by MarketBeat.

ImmunityBio currently has a consensus target price of $25.00, suggesting a potential upside of 55.38%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than ImmunityBio.

Valuation and Earnings

This table compares ImmunityBio and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares ImmunityBio and Sigilon Therapeutics' net margins, return on equity and return on assets.

Summary

Sigilon Therapeutics beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for BioAtla and Sigilon Therapeutics, as reported by MarketBeat.

BioAtla currently has a consensus target price of $58.00, suggesting a potential upside of 20.26%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than BioAtla.

Valuation and Earnings

This table compares BioAtla and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares BioAtla and Sigilon Therapeutics' net margins, return on equity and return on assets.

Summary

BioAtla beats Sigilon Therapeutics on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Immunocore and Sigilon Therapeutics, as reported by MarketBeat.

Immunocore currently has a consensus target price of $54.3333, suggesting a potential upside of 68.63%. Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sigilon Therapeutics is more favorable than Immunocore.

Valuation and Earnings

This table compares Immunocore and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Profitability

This table compares Immunocore and Sigilon Therapeutics' net margins, return on equity and return on assets.

Summary

Sigilon Therapeutics beats Immunocore on 3 of the 3 factors compared between the two stocks.

Cricut (NASDAQ:EWTX) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Cricut and Sigilon Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cricut and Sigilon Therapeutics, as reported by MarketBeat.com.

Sigilon Therapeutics has a consensus price target of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Cricut.

Valuation & Earnings

This table compares Cricut and Sigilon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Summary

Sigilon Therapeutics beats Cricut on 2 of the 2 factors compared between the two stocks.

Kinnate Biopharma (NASDAQ:KNTE) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares Kinnate Biopharma and Sigilon Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Kinnate Biopharma and Sigilon Therapeutics, as reported by MarketBeat.com.

Kinnate Biopharma currently has a consensus price target of $52.00, suggesting a potential upside of 73.39%. Sigilon Therapeutics has a consensus price target of $53.75, suggesting a potential upside of 208.38%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Kinnate Biopharma.

Valuation & Earnings

This table compares Kinnate Biopharma and Sigilon Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Summary

Kinnate Biopharma beats Sigilon Therapeutics on 2 of the 3 factors compared between the two stocks.